StemRIM Past Earnings Performance
Past criteria checks 3/6
StemRIM's earnings have been declining at an average annual rate of -3.5%, while the Biotechs industry saw earnings growing at 23% annually. Revenues have been growing at an average rate of 9.2% per year. StemRIM's return on equity is 1.8%, and it has net margins of 7.6%.
Key information
-3.5%
Earnings growth rate
0.4%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | 9.2% |
| Return on equity | 1.8% |
| Net Margin | 7.6% |
| Next Earnings Update | 12 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How StemRIM makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 2,350 | 179 | 607 | 1,560 |
| 31 Oct 23 | 2,350 | 214 | 610 | 1,545 |
| 31 Jul 23 | 2,350 | 168 | 609 | 1,567 |
| 30 Apr 23 | 2,350 | 332 | 556 | 1,479 |
| 31 Jan 23 | 0 | -1,957 | 545 | 1,438 |
| 31 Oct 22 | 0 | -1,971 | 537 | 1,433 |
| 31 Jul 22 | 22 | -1,948 | 549 | 1,421 |
| 30 Apr 22 | 1,212 | -788 | 546 | 1,439 |
| 31 Jan 22 | 1,212 | -813 | 517 | 1,485 |
| 31 Oct 21 | 1,212 | -811 | 473 | 1,521 |
| 31 Jul 21 | 1,400 | -582 | 437 | 1,523 |
| 30 Apr 21 | 1,910 | -501 | 461 | 1,929 |
| 31 Jan 21 | 2,310 | 89 | 437 | 1,762 |
| 31 Oct 20 | 2,310 | 358 | 386 | 1,553 |
| 31 Jul 20 | 2,100 | 347 | 321 | 1,356 |
| 30 Apr 20 | 400 | -662 | 258 | 752 |
| 31 Jul 19 | 100 | -721 | 185 | 640 |
| 31 Jul 18 | 200 | -323 | 122 | 453 |
| 31 Jul 17 | 300 | -123 | 111 | 349 |
Quality Earnings: 4599 has high quality earnings.
Growing Profit Margin: 4599 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4599 has become profitable over the past 5 years, growing earnings by -3.5% per year.
Accelerating Growth: 4599 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 4599 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: 4599's Return on Equity (1.8%) is considered low.